Shinohara Y, Matsubuchi T, Kawagoe H, Nagai K, Kanamaru A, Horiuchi A, Hasegawa H, Kitani T, Tsubakio T, Yonezawa T, Masaoka T, Shibata H
Jpn J Antibiot. 1983 Feb;36(2):391-7.
Seventy-six patients with severe infection accompanying hematologic disorders including leukemia and lymphoma were treated with intravenous drip infusion of cefotetan (CTT). Of the 66 cases in whom the efficacy could be evaluated, 22 cases responded markedly and 16 cases moderately, the effective rate being 57.6%. It is impressed that more cases responded markedly to CTT than to any other antibiotics previously studied. None of the cases revealed serious side effects attributable to CTT. These results indicate that CTT is an effective and safe antibiotic for the treatment of severe infection accompanying hematologic disorders. As CTT was administered to special cases under marked decrease of neutrocyte, the importance of neutrocyte in the treatment of infection was also indicated.
76例伴有血液系统疾病（包括白血病和淋巴瘤）的严重感染患者接受了头孢替坦（CTT）静脉滴注治疗。在66例可评估疗效的病例中，22例显效，16例有效，有效率为57.6%。令人印象深刻的是，对CTT显效的病例比对先前研究过的任何其他抗生素都多。所有病例均未出现归因于CTT的严重副作用。这些结果表明，CTT是治疗伴有血液系统疾病的严重感染的一种有效且安全的抗生素。由于CTT是在中性粒细胞显著减少的特殊情况下给药的，这也表明了中性粒细胞在感染治疗中的重要性。
